HIT TO MEDICAL MARIJUANA ‘ENDOCANNABINOID’ CROWD.
Lenabasum, an oral synthetic endocannabinoid-mimetic that preferentially binds to the cannabinoid receptor type 2 (CB2) fails to to sufficiently separate from placebo.
Imagine buying 10,000 shares on margin Friday. $90,000 ($45,000 equity) was worth $23,000 this morning. Since you still owe the house the $45,000 you borrowed – you are NEGATIVE $22,000.
Mix that with a Labor Day hangover. Plop, plop. fizz, fizz..
BIOTECH NIGHTMARES, THEY HAPPEN
WALL STREET’S BEST CAUGHT OFF GUARD. JUST A LITTLE
“Unprecedented improvement was observed in subjects on placebo added to background drug therapy!” What the?
Corbus Pharma’s lenabasum flunks late-stage systemic sclerosis study, shares down 77%
‘We’re ahead of the pack’ in the Cannabinoid Drug Space, says CEO
We added Corbus to the Watch List last April – so close to a double! Adding Corbis Pharma (CRBP) $5.55 to Watch List.
